ImmunoGen Inc. received a commitment worth at least $62 million from Aventis SA, which in turn acquired a large share of ImmunoGen's pipeline as part of an agreement to jointly develop antibody-based cancer products. And the deal could get sweeter from there. (BioWorld Today) Read More
